Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
PRINCETON, N.J., May 30 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) is scheduled to host a webcast review of the
ipilimumab data presented during the Annual Meeting of the American
Society of Clinical
Oncology (ASCO) in Chicago. As previously announced, the live
webcast will begin at 8:00 a.m. Eastern Time / 7:00 a.m. Central
Time on Monday, June 2, 2008. Medarex senior management will
be joined by Jedd D. Wolchok, M.D., Ph.D., Director of
Immunotherapy Clinical Trials at Memorial Sloan-Kettering Cancer
Center in New York.
The webcast can be accessed on Medarex's website at www.medarex.com and will be archived and available for at least 14 days.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human
antibody-based therapeutics to treat life-threatening and
debilitating diseases, including cancer, inflammation, autoimmune
disorders and infectious diseases. Medarex applies its UltiMAb(R)
technology and product development and clinical manufacturing
experience to generate, support and potentially commercialize
a
broad range of fully human antibody product candidates for itself
and its partners. More than 40 of these therapeutic product
candidates derived from Medarex technology are in human clinical
testing or have had INDs submitted for such trials, with seven of
the most advanced product candidates currently in Phase 3 clinical
trials or the subject of regulatory applications for marketing
authorization. Medarex is committed to building value by developing
a diverse pipeline of antibody products to address the world's
unmet healthcare needs. For more information about Medarex, visit
its website at
www.medarex.com.
Medarex, the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
CONTACT: Laura S. Choi, Investor Relations, +1-609-430-2880,
ext. 2216, or Nichol Harber, Corporate Communications (media),
+1-609-430-2880, ext. 2214, both of Medarex, Inc.
Company News On-Call: http://www.prnewswire.com/comp/108265.html
Web site: http://www.medarex.com
Posted: May 2008
